- Home
- WIW vs CTNM Comparison
WIW vs CTNM Comparison
Compare WIW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WIW | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 489.4M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | WIW | CTNM |
|---|---|---|
| Price | $8.36 | $14.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 313.5K | 230.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.29 | $3.72 |
| 52 Week High | $9.03 | $16.33 |
Technical Indicators
Market Signals| Indicator | WIW | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 63.30 |
| Support Level | $8.34 | $13.86 |
| Resistance Level | $8.61 | $15.60 |
| Average True Range (ATR) | 0.06 | 1.02 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 21.31 | 97.67 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.